During the last session, Vor Biopharma Inc (NASDAQ:VOR)’s traded shares were 0.46 million, with the beta value of the company hitting -0.40. At the end of the trading day, the stock’s price was $0.79, reflecting an intraday loss of -0.77% or -$0.01. The 52-week high for the VOR share is $3.14, that puts it down -297.47 from that peak though still a striking 20.25% gain since the share price plummeted to a 52-week low of $0.63. The company’s market capitalization is $54.25M, and the average intraday trading volume over the past 10 days was 0.51 million shares, and the average trade volume was 988.74K shares over the past three months.
Vor Biopharma Inc (VOR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. VOR has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.31.
Vor Biopharma Inc (NASDAQ:VOR) trade information
Vor Biopharma Inc (VOR) registered a -0.77% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.77% in intraday trading to $0.79, hitting a weekly high. The stock’s 5-day price performance is -8.55%, and it has moved by 13.13% in 30 days. Based on these gigs, the overall price performance for the year is -55.37%. The short interest in Vor Biopharma Inc (NASDAQ:VOR) is 1.71 million shares and it means that shorts have 2.99 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 86.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, VOR is trading at a discount of -659.49% off the target high and -659.49% off the low.
Vor Biopharma Inc (VOR) estimates and forecasts
Statistics show that Vor Biopharma Inc has underperformed its competitors in share price, compared to the industry in which it operates. Vor Biopharma Inc (VOR) shares have gone down -49.20% during the last six months, with a year-to-date growth rate less than the industry average at 11.43% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 19.78% this quarter and then jump 31.56% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -73.43%. While earnings are projected to return 10.22% in 2024.
VOR Dividends
Vor Biopharma Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Vor Biopharma Inc (NASDAQ:VOR)’s Major holders
Vor Biopharma Inc insiders own 1.17% of total outstanding shares while institutional holders control 81.25%, with the float percentage being 82.21%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 92.0 institutions own stock in it. As of 2024-06-30, the company held over 22.75 million shares (or 33.439% of all shares), a total value of $22.75 million in shares.
The next largest institutional holding, with 7.08 million shares, is of FMR LLC’s that is approximately 10.4009% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $7.08 million.
Also, the Mutual Funds coming in first place with the largest holdings of Vor Biopharma Inc (VOR) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Fidelity Growth Company Fund owns about 1.44 shares. This amounts to just over 2.09 percent of the company’s overall shares, with a $1.14 million market value. The same data shows that the other fund manager holds slightly less at 1.39, or about 2.02% of the stock, which is worth about $1.09 million.
